ND-003 (Numab )

N/A

Report date: 2026/03/19 17:16:45

Base Information

Drug NameND-003 (Numab )
Drug Alias NameND003
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-CD3Interleukin-5 receptor subunit alpha inhibitors
TargetsT cell surface glycoprotein CD3Interleukin-5 receptor subunit alpha
Therapy Area/IndicationsAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNumab Therapeutics Ag
China Registration ClassN/A

Develop Information

Active CompaniesNumab Therapeutics Ag
Inactive CompaniesN/A
Active IndicationsAsthma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A